Page last updated: 2024-09-05

sb 203580 and roflumilast n-oxide

sb 203580 has been researched along with roflumilast n-oxide in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (roflumilast n-oxide)	Trials (roflumilast n-oxide)	Recent Studies (post-2010) (roflumilast n-oxide)
3,489	4	1,137	42	9	30

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albrecht, W; Bauer, SM; Laufer, SA; Unger, A	1

Other Studies

1 other study(ies) available for sb 203580 and roflumilast n-oxide

Article	Year
Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. Journal of medicinal chemistry, 2017, 07-13, Volume: 60, Issue:13 Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Discovery; Humans; Imidazoles; Inflammation; Mitogen-Activated Protein Kinase 14; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha	2017

Article

Year

Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.

Journal of medicinal chemistry, 2017, 07-13, Volume: 60, Issue:13

Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Discovery; Humans; Imidazoles; Inflammation; Mitogen-Activated Protein Kinase 14; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha

2017